Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial

20260 citationsJournal Article

Authors

Deborah B. Doroshow · Yale Cancer Center

Geoffrey I. Shapiro · Dana-Farber Cancer Institute

Khanh Do · Dana-Farber Cancer Institute

Vicki L. Keedy · Vanderbilt University

H. Mahdi · University of Pittsburgh Medical Center

Davendra Sohal · Cleveland Clinic

Navid Hafez ·

Abstract

The study failed to meet its primary end point of ORR. DDR and homologous recombination repair defects are not consistently actionable with olaparib as monotherapy or in combination with other targeted therapies in a histology-agnostic manner.

Topics & Keywords

PARP inhibition in cancer therapy DNA Repair Mechanisms Cell death mechanisms and regulation

Publication Details

Published in: Cancer

Volume 132, Issue 6, pp. e70332-e70332

DOI: 10.1002/cncr.70332

Field-Weighted Citation Impact: 0.00

Command Palette

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial

Authors

Abstract

Topics & Keywords

Publication Details